LOGIN  |  REGISTER
Terns Pharmaceuticals
Compass Therapeutics

Agilent Technologies Announces Cash Dividend of 24.8 Cents per Share

May 21, 2025 | Last Trade: US$107.30 28.80 -21.16

SANTA CLARA, Calif. / May 21, 2025 / Business Wire / Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on July 23, 2025, to all shareholders of record as of the close of business on July 1, 2025.

The timing and amounts of future dividends are subject to determination and approval by Agilent’s board of directors.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Forward-Looking Statements

This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the company’s dividend program and future payment obligations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties are detailed in Agilent’s filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the fiscal year ended Oct. 31, 2024. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page